Company profile
Cellectis
Cellectis is developing life-changing product candidates to target and eradicate cancer cells.
- Industry
- Biotechnology Research
- Employees
- 241
- Headquarters
- Paris
- Founded
- 1999
- Office locations
- 3
Cellectis company summary
Cellectis is a company in the Biotechnology Research industry, headquartered in Paris, founded in 1999. On LinkedIn the company has around 241 employees. The company lists 3 office locations. Its listed specialties include Gene editing, Life sciences, Oncology, T-Cell therapies, genome engineering.
What technology does Cellectis use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Cellectis
Cellectis is a global, clinical-stage biopharmaceutical company. As pioneers and innovators in our field, we are driven by a single mission: to develop breakthrough treatments for patients with unmet medical needs. With 26 years of expertise, we operate a best-in-class genome editing platform focused on immuno-oncology and gene therapy. By leveraging our proprietary gene-editing technologies, we engineer allogeneic CAR-T cells designed to recognize and eliminate cancer cells. Currently, our two lead clinical programs are evaluating therapies for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). As a fully integrated leader in genome editing and allogeneic CAR-T cell research, we maintain complete end-to-end control over our manufacturing process. This vertical integration ensures quality across the board: • Paris, France: Production of starting materials • Raleigh, NC (USA): Manufacturing of the finished CAR-T products We have established powerful collaborations with industry leaders, including AstraZeneca and Allogene Therapeutics, to accelerate the development of product candidates across oncology, immunology, and rare diseases. Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/ Follow our other social media account on X. TALEN® is a registered trademark owned by the Cellectis Group.
Specialties
Where is Cellectis located?
Cellectis lists 3 office locations.
Compare companies similar to Cellectis
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Cellectis cellectis.com | Biotechnology Research | 241 | 1999 | Paris |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Cellectis
What does Cellectis do?
Cellectis is a global, clinical-stage biopharmaceutical company. As pioneers and innovators in our field, we are driven by a single mission: to develop breakthrough treatments for patients with unmet medical needs. With 26 years of expertise, we operate a best-in-class genome editing platform focused on immuno-oncology and gene therapy. By leveraging our proprietary gene-editing technologies, we engineer allogeneic CAR-T cells designed to recognize and eliminate cancer cells. Currently, our two lead clinical programs are evaluating therapies for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). As a fully integrated leader in genome editing and allogeneic CAR-T cell research, we maintain complete end-to-end control over our manufacturing process. This vertical integration ensures quality across the board: • Paris, France: Production of starting materials • Raleigh, NC (USA): Manufacturing of the finished CAR-T products We have established powerful collaborations with industry leaders, including AstraZeneca and Allogene Therapeutics, to accelerate the development of product candidates across oncology, immunology, and rare diseases. Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/ Follow our other social media account on X. TALEN® is a registered trademark owned by the Cellectis Group.
How many employees does Cellectis have?
Cellectis has around 241 employees on LinkedIn.
Where is Cellectis headquartered?
Cellectis is headquartered in Paris.
Where does Cellectis have offices?
Cellectis lists 3 office locations, including Paris, 75013, FR; New York, NY, US; Raleigh, North Carolina, US.
When was Cellectis founded?
Cellectis was founded in 1999.
Build a lead list from companies like Cellectis
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.